Previous 10 | Next 10 |
2024-02-24 05:52:00 ET One good year leads to another. That's typically been the pattern for the Nasdaq Composite index since its creation in 1971. The positive years for the index outnumber the negative years by nearly 3 to 1. History is on the side of investors hoping for the Nasd...
A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) rose 2.8% to $11.65 on volume of 139,655,455 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 2.1% to $4.39 on volume of 127,826,661 shares SoundHound AI Inc. (SOUN) rose 1.6% to $3.82 on volume of...
2024-02-20 00:37:48 ET Summary Dividend growth investors saw two dozen increases in the first half of February. Among these were two companies with nearly 70 years of dividend growth each – 3M (66 years) and Genuine Parts Company (68 years). The number of dividend incre...
2024-02-18 06:39:11 ET Summary This article provides a monthly dashboard with aggregate industry metrics in the healthcare sector. Fast facts on IDNA, a thematic and volatile biotech ETF. We conclude with 10 healthcare stocks cheaper than their peers in February. ... ...
A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) rose 2.3% to $11.595 on volume of 119,263,238 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 0.8% to $4.3323 on volume of 111,414,526 shares SoundHound AI Inc. (SOUN) rose 0.0% to $3.7601 on volu...
2024-02-16 15:12:17 ET Summary The narrow rally trend in 2023 is expected to continue in 2024, making overweighting profitable big-tech stocks a successful strategy. The best intersections of quality, growth, and value in the market exist in mega-cap tech land. Most other stoc...
2024-02-16 13:52:08 ET More on Inventiva Inventiva reports 9M results Seeking Alpha’s Quant Rating on Inventiva Historical earnings data for Inventiva Financial information for Inventiva Read the full article on Seeking Alpha For furthe...
2024-02-16 04:46:46 ET Gilead Sciences ( NASDAQ: GILD ) said on Thursday that enrollments to test its cancer drug, magrolimab, on solid tumors has been paused globally after data indicated an increased risk of death.... Read the full article on Seeking Alpha For further ...
2024-02-15 22:06:27 ET Summary Gilead Sciences' stock has been trading in the red for the past seven days consecutively. The stock has been stagnant since 2015, but the company's business prospects are improving. Gilead has a strong pipeline of drugs, including treatments for ...
2024-02-15 10:18:57 ET Summary MacroGenics, Inc. has a pipeline of promising drugs including Vobramitamab Duocarmazine, Lorigerlimab, Tebotelimab, MGD024, and IMGC936. The company has a strong financial position as of their latest report. MacroGenics faces both strengths and r...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...